OnoSec Medical, FYE Financial Review, Analysts Target and Upcoming SITC Presentation

OncoSec Medical Incorporated (NASDAQ: ONCS) is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.

On October 25th, the company released financial results for the fourth quarter and fiscal year ended July 31, 2017. In the quarter, ONCS made significant progress in advancing the development of its lead clinical program, ImmunoPulse® IL-12, which it believes could provide a meaningful clinical benefit to metastatic melanoma patients with limited or no treatment options.

The company remains focused on advancing its PISCES/KEYNOTE-695 registration-directed trial to address this significant unmet medical need through an innovative accelerated pathway.

Company’s clinical development plans are progressing fast, and ONCS is scheduled for Late-breaking poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd 2017 Annual Meeting to be held in National Harbor, MD on November 8-12, 2017.

Immunotherapy is a very hot topic in cancer at the moment, but there are no drugs on the markets that include this sort of inducing technology. Therefore, if ONCS can get this one on the market, it could be a breakthrough in the space.

ImmunoPulse® IL-12: The Next Innovation for Oncology:

There are the potential upside catalysts for the company and, if news hits press favorably, the stock of the company will be on a growth trajectory. Even if it misses, the subsequent dip in share price will serve as an option to make a position for the eventual upside run.


Several equities research analysts recently issued favorable reports on ONCS shares. The analyst’s forecasts oscillate between $5.00 to $6.00. On average, the consensus target is $5.33 in the next year.


About the company: OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.



ImmunoPulse® IL-12 for stage III/IV relapsed/refractory melanoma positioned for accelerated approval.

  • Initial data mid-2018 seek feedback on accelerated approval
  • Potential approval in 2019 via accelerated pathway
  • Global PISCES trial in melanoma

ImmunoPulse IL-12 + checkpoint inhibitor in low-TIL (cold) at 50% BORR

  • Opportunity to expand 1st line anti-PD-1 response beyond 30-35%

ImmunoPulse IL-12 converts checkpoint inhibitor non-responders to responders Ø60-70% of melanoma patients do not respond to checkpoint inhibitors 1st line


Present Trials:

Anticipated near-term milestones:


Other recent highlights:

  • Presented positive Phase 2 data with ImmunoPulse IL-12 as monotherapy and in combination with pembrolizumab at the 2017 9th World Congress of Melanoma – A Joint Meeting of the Society for Melanoma Research.
  • Initiated global, open-label, registration-directed clinical trial, PISCES/KEYNOTE-695, of ImmunoPulse IL-12 in combination with pembrolizumab.
  • Enrolling patients with unresectable metastatic melanoma who have progressed or are progressing on an anti-PD-1 therapy.
  • ImmunoPulse IL-12 granted Fast Track and Orphan Drug Designation in the U.S.
  • Clinical trial collaboration and supply agreement with Merck (known as MSD outside the US and Canada); attained KEYNOTE status.
  • Corporate Highlights: Added industry veterans Dr. Annalisa Jenkins, MBBS, FRCP and Daniel J. O’Connor to the Board of Directors; Initiated a Technology Access Program collaboration with Jounce Therapeutics; and, Raised and obtained commitments for $8.1 Million in offerings priced at or above market price.


Q4 and FYE 2017 Financial Results:

  • There were no revenues for the fiscal years ended July 31, 2017, or July 31, 2016.
  • At July 31, 2017, OncoSec had $11.4 million in cash and cash equivalents, as compared to $28.7 million of cash and cash equivalents at July 31, 2016. OncoSec expects these funds to be sufficient to allow it to continue to operate its business in the third calendar quarter of 2018.
  • For the fourth quarter of fiscal 2017 and the fiscal year ended July 31, 2017, OncoSec reported a net loss of $5.8 million and $21.4 million, or $0.28 per share and $1.06 per share, respectively, compared to a net loss of $6.6 million and $26.9 million, or $0.39 per share and $1.63 per share, respectively, for the same period last year.
  • Upcoming Results: OncoSec Medical Incorporated is likely to release their next quarterly earnings announcement on Thursday, December 14th, 2017


Key risk factors and potential stock drivers:

The company is optimistic about the positive outcome of the SITC meeting. This meeting will be a critical catalyst for the company going forward.

Notwithstanding promising data and partnerships, ONCS does not have a product yet approved by FDA. There is a risk that their potential drugs might fail during the clinical trials.

The outcome of the upcoming milestones/catalysts could be the near-term trigger for the company. Any non-favorable developments could impinge the business and financial risk profile of the company.

The company may experience financial, regulatory, or operational difficulties, which may impair its ability to commercialize their drug products.


Stock Chart:

On Friday, November 3rd, 2017, ONCS closed at $1.32 on an above average volume of 1.62 million shares exchanging hands. Market capitalization is $39.08 million. The current RSI is 63.55

In the past 52 weeks, shares of ONCS have traded as low as $0.88 and as high as $1.90

At $1.32, shares of ONCS are trading above its 50-day moving average (MA) at $1.07 and above its 200-day MA at $1.14 as well.

The present support and resistance levels for the stock are at $1.24 & $1.43 respectively.


Welcome to Traders News Source

Our track record speaks for itself…


Traders News Source recent profiles and track record, 487% in verifiable potential gains for our members on 3 small cap alerts alone! These are just three examples from over two dozen winners this year. 


January 31st, 2017 (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days- http://finance.yahoo.com/news/himax-technologies-review-4q-2016-130000319.html


May 23rd, 2016- (NYSE: XXII) opened at $.87/share hit a high of $3.03/share so far our member potential gains- 248% – http://mailchi.mp/tradersnewssource/updates-5-of-our-profiles-for-212-400-and-whats-coming-next?e=[UNIQID]


October 31st, 2017 (NASDAQ: PYDS) Although we have been covering this security for over a year, our recent coverage October 31st, 2017 opened at $1.45/share hit $4.10 within three days for gains of over 150%- http://mailchi.mp/tradersnewssource/update-pyds-back-in-the-value-zone-with-news-out?e=[UNIQID]


So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletter. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

Big Opportunities Trading Small Cap Stocks

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Traders” to the phone number “25827” from your cell phone***





Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.

We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.

When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.

17B Disclosure

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.

Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.